Paul E. Sax, MD is the Editor-in-Chief, Journal Watch HIV/AIDS Clinical Care and Clinical Director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital.
Learn more about HIV and ID Observations.
(3 votes, average: 5.00 out of 5)In the recent post on the approval of generic Combivir — and the lack of availability of generic Epivir (lamivudine, 3TC), which was both anticipated and likely to be more useful — I speculated there were several possible causes of this surprising turn of events.
But ultimately I concluded, “In sum, the real reason there’s no generic 3TC remains a mystery.”
Last week, however, I received a fascinating email from an industry representative, who has asked that I summarize the turn of events from their perspective:
Mystery solved — and thank you for the clarification.
But I hasten to add that this information was not widely known by HIV/ID specialists, and furthermore not easy to find. One of my colleagues has likened reading rulings on patent law for generics akin to learning English as a second language, a very apt analogy.
A great way to be introduced to patent law for generics and the sordid strategies used by pharmaceutical industry is through the reading of “The Truth About the Drug Companies” by Marcia Angell.